^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ABCC6 (ATP Binding Cassette Subfamily C Member 6)

i
Other names: ABCC6, ATP Binding Cassette Subfamily C Member 6, MRP6, EST349056, MLP1, URG7, ARA, ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 6, Anthracycline Resistance-Associated Protein, ATP-Binding Cassette Sub-Family C Member 6, Multi-Specific Organic Anion Transporter E, Multidrug Resistance-Associated Protein 6, MOAT-E, PXE, Pseudoxanthoma Elasticum, URG7 Protein, ABC34, GACI2, MOATE, PXE1
Associations
Trials
3d
Novel Insights into the Enigmatic Genetics of Male Breast Cancer in China. (PubMed, Pathophysiology)
As the inaugural germline genomic investigation of MaBC in a Han Chinese population, this work reveals clinically actionable alterations with diagnostic and therapeutic implications. These discoveries not only advance our understanding of MaBC's molecular architecture but also underscore the critical need for dedicated research into this malignancy.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • RAD50 (RAD50 Double Strand Break Repair Protein) • ABCC6 (ATP Binding Cassette Subfamily C Member 6)
|
BRCA2 mutation • PALB2 mutation
2ms
PURI-PXE: Purinergic Compounds in Pseudoxanthoma Elasticum (clinicaltrials.gov)
P=N/A, N=45, Not yet recruiting, Centre Hospitalier Universitaire de Nice
New trial
|
ABCC6 (ATP Binding Cassette Subfamily C Member 6)
5ms
ABCC6 Transporter Contributed to Cisplatin Resistance on Bladder Cancer. (PubMed, Int J Med Sci)
Further analysis showed that ABCC6 knockdown affected autophagy-related markers, and inhibition of autophagy using bafilomycin A1 (BafA1) and chloroquine (CQ) reversed cisplatin resistance. Targeting autophagy may offer a potential strategy to overcome chemoresistance in BLCA. Future research should focus on validating these findings in clinical samples and exploring ABCC6 inhibitors or autophagy modulators as therapeutic options.
Journal
|
ABCC6 (ATP Binding Cassette Subfamily C Member 6)
|
cisplatin • chloroquine phosphate
7ms
Genetic Variants Influence the Severity of Oral Mucositis in Pediatric Osteosarcoma Patients. (PubMed, Oral Dis)
Oral mucositis risk and severity in a pediatric population being treated for OS with HDMTX, doxorubicin, and cisplatin were associated with genes in the ABC family (ABCA3, ABCC2, and ABCC6 genes).
Journal
|
ABCC2 (ATP Binding Cassette Subfamily C Member 2) • ABCA3 (ATP Binding Cassette Subfamily A Member 3) • ABCC6 (ATP Binding Cassette Subfamily C Member 6)
|
cisplatin • doxorubicin hydrochloride
8ms
Association of ATP-binding cassette transporter genomic alterations and expressions with patient survival in breast and prostate cancer. (PubMed, Physiol Rep)
However, we found reduced relapse-free survival correlating with reduced RNA expression in select ABC transporters in 4929 breast cancer patients in a KMplot analysis. These findings highlight the potential role of ABC transporters in prostate and breast cancer prognosis and warrant further investigation into their therapeutic implications.
Clinical • Journal
|
ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • ABCC3 (ATP Binding Cassette Subfamily C Member 3) • CFTR (CF Transmembrane Conductance Regulator) • ABCA2 (ATP Binding Cassette Subfamily A Member 2) • ABCA3 (ATP Binding Cassette Subfamily A Member 3) • ABCC6 (ATP Binding Cassette Subfamily C Member 6) • ABCC9 (ATP Binding Cassette Subfamily C Member 9) • ABCG1 (ATP Binding Cassette Subfamily G Member 1)
9ms
Managing Choroidal Neovascularization in Pseudoxanthoma Elasticum: Outcomes of Vitrectomy and Intravitreal Ranibizumab/Aflibercept Therapy-A Case Report. (PubMed, Case Rep Ophthalmol Med)
Management of CNV in PXE involves the prompt use of intravitreal anti-VEGF injections and vitrectomy with tissue plasminogen activator (tPA) for controlling CNV activity and submacular hemorrhage. Ophthalmologists should consider PXE in patients presenting with characteristic skin and eye findings and refer them for dermatological evaluation as necessary.
Journal
|
ABCC6 (ATP Binding Cassette Subfamily C Member 6)
|
Eylea (aflibercept intravitreal) • Lucentis (ranibizumab)
1year
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE (clinicaltrials.gov)
P1/2, N=10, Completed, Inozyme Pharma | Trial primary completion date: Nov 2024 --> Jul 2024 | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024
Trial completion • Trial completion date • Trial primary completion date
|
ABCC6 (ATP Binding Cassette Subfamily C Member 6)
1year
Absolute membrane protein abundance of P-glycoprotein, breast cancer resistance protein, and multidrug resistance proteins in term human placenta tissue and commonly used cell systems: Application in physiologically based pharmacokinetic modeling of placental drug disposition. (PubMed, Drug Metab Dispos)
SIGNIFICANCE STATEMENT: This study quantified the expression of key placental transporters in human placenta and various placental cell lines, revealing significant expression variations. By integrating these data with physiologically based pharmacokinetic modeling, the study highlights the importance of transporter abundance data in understanding and predicting placental drug disposition, essential for maternal and fetal health during pregnancy.
PK/PD data • Journal
|
ABCC6 (ATP Binding Cassette Subfamily C Member 6)
over1year
Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification. (PubMed, Kidney Int)
TYK2 inhibition by deucravacitinib, a selective, allosteric oral immunosuppressant used in psoriasis treatment, not only blunted the effects of LIF, but also interfered with the pro-calcific effects induced by phosphate...Thus, our observations indicate a role for LIF in CKD-associated vascular calcification. Hence, the effects of LIF identify a central pro-calcific role of TYK2 signaling, which may be a future target to reduce the burden of vascular calcification in CKD.
Journal
|
IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • LIFR (LIF Receptor Subunit Alpha) • TYK2 (Tyrosine Kinase 2) • ABCC6 (ATP Binding Cassette Subfamily C Member 6) • LIF (LIF Interleukin 6 Family Cytokine)
over1year
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE (clinicaltrials.gov)
P1/2, N=10, Active, not recruiting, Inozyme Pharma | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
Trial completion date • Trial primary completion date
|
ABCC6 (ATP Binding Cassette Subfamily C Member 6)
2years
Rare copy-number variants as modulators of common disease susceptibility. (PubMed, Genome Med)
Our results shed light on the prominent role of rare CNVs in determining common disease susceptibility within the general population and provide actionable insights for anticipating later-onset comorbidities in carriers of recurrent CNVs.
Journal
|
BRCA1 (Breast cancer 1, early onset) • ABCC6 (ATP Binding Cassette Subfamily C Member 6)
2years
Journal
|
TP53 (Tumor protein P53) • PBRM1 (Polybromo 1) • CHD4 (Chromodomain Helicase DNA Binding Protein 4) • XIRP2 (Xin Actin Binding Repeat Containing 2) • ABCC6 (ATP Binding Cassette Subfamily C Member 6) • PKHD1 (PKHD1 Ciliary IPT Domain Containing Fibrocystin/Polyductin)
|
TP53 mutation • PBRM1 mutation • VHL mutation